Wolfe Research analyst Alex Zukin maintains DocuSign (NASDAQ:DOCU) with a Underperform and raises the price target from $50 to $53.
Comera Life Sciences Announces Collaboration With Quality Chemical Laboratories To Secure Proprietary Supply Of SQore Excipients
– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to support product development needs –
WOBURN, Mass.,
